Covered recipient · General Payments record
KIRA M ALATAR
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$4,273.12
- Reported across 278 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $284.59 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $91.02 | 6 |
| Amgen Inc. | $67.06 | 4 |
| Abbott Laboratories | $46.98 | 2 |
| Phathom Pharmaceuticals, Inc. | $30.85 | 2 |
| Lilly USA, LLC | $17.80 | 1 |
| PFIZER INC. | $17.08 | 1 |
| INTRA-SANA LABORATORIES | $13.80 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $24.28 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125230237 | CMS |
| Abbott Laboratories | $22.70 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125230241 | CMS |
| Amgen Inc. | $16.60 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117186603 | CMS |
| Amgen Inc. | $17.02 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117186605 | CMS |
| Amgen Inc. | $16.21 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117186607 | CMS |
| Amgen Inc. | $17.23 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117186609 | CMS |
| Intra-Sana Laboratories | $13.80 | 01/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1138616911 | CMS |
| Lilly USA, LLC | $17.80 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135114020 | CMS |
| Novo Nordisk Inc | $13.64 | 04/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097229150 | CMS |
| Novo Nordisk Inc | $14.69 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096862669 | CMS |
| Novo Nordisk Inc | $16.17 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096644638 | CMS |
| Novo Nordisk Inc | $15.99 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097276821 | CMS |
| Novo Nordisk Inc | $17.35 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096669809 | CMS |
| Novo Nordisk Inc | $13.18 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096952284 | CMS |
| PFIZER INC. | $17.08 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131292314 | CMS |
| Phathom Pharmaceuticals, Inc. | $14.00 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151033490 | CMS |
| Phathom Pharmaceuticals, Inc. | $16.85 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151033492 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.